Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Cocrystal Pharma Inc (COCP) USD0.01

Sell:$1.65 Buy:$1.72 Change: $0.12 (6.70%)
NASDAQ:2.13%
Market closed |  Prices as at close on 13 July 2020 | Switch to live prices |
Sell:$1.65
Buy:$1.72
Change: $0.12 (6.70%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 13 July 2020 | Switch to live prices |
Sell:$1.65
Buy:$1.72
Change: $0.12 (6.70%)
Market closed |  Prices as at close on 13 July 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.

Contact details

Address:
19805 N Creek Pkwy
BOTHELL
98011-8251
United States
Telephone:
+1 (786) 4591831
Website:
https://www.cocrystalpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
COCP
ISIN:
US19188J3005
Market cap:
$93.33 million
Shares in issue:
52.14 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Gary Wilcox
    Chairman of the Board, Chief Executive Officer
  • Sam Lee
    President
  • James Martin
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.